CD276 and glioblastoma: Gaining inspiration from the preclinical promise exhibited by Majzner et al. [109] and Tang et al. [110], a phase I/II clinical trial [111] has been initiated in 2022 to assess the effect of B7-H3 CAR T cell therapy in between two successive cycles of temozolomide in the treatment of recurrent and/or refractory glioblastoma.